/Companies

AMLo Biosciences

Newcastle upon Tyne, GB · 8 known investors

Find your way into AMLo Biosciences

Sign up to see every warm intro you have to AMLo Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AMLo Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.

Founders & leadership

PLPenny Lovat
Penny LovatChief Scientific Officer

Investors · 8

Also in the syndicate · 3

Ascension's Life FundConduit's EIS Impact FundFuture Planet Capital's BIF Opportunities Fund

Companies House · registry record

View on Companies House ↗
Insolvency historyConfirmation statement overdue
Registered name
AMLO BIOSCIENCES LIMITED
Company number
11004534
Status
Administration
Company type
Private limited company
Incorporated
10 Oct 2017
Registered office
C/O GRANT THORNTON UK ADVISORY & TAX LLP, 11th Floor Landmark St Peters Square Oxford Street, Manchester, M1 4PB
Nature of business (SIC)
71200 — Technical testing and analysis
Accounts
last made up to 30 Nov 2024 · next due 31 Aug 2026
Confirmation statement
last made up to 9 Oct 2024 · next due 23 Oct 2025

Current officers · 5

  • Marie Beagley Labus — director, appointed 5 Dec 2017
  • Penny Emma Lovat — director, appointed 5 Dec 2017
  • David Lawrence Macdonald — director, appointed 1 Jun 2021
  • Vanessa Jane Meaney — director, appointed 1 Mar 2021
  • Sandy Blackadder Primrose — director, appointed 24 Nov 2020

Source: Companies House public register · retrieved 7 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does AMLo Biosciences do?
AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.
Who are AMLo Biosciences's investors?
AMLo Biosciences's investors include Conduit Connect, Esperante Ventures, Future Planet Capital, Milltrust International Group, Northstar Ventures.
Where is AMLo Biosciences headquartered?
AMLo Biosciences is headquartered in Newcastle upon Tyne, GB.